Isomorphic Labs Raises $5 Billion to Advance AI-Designed Medicines
Isomorphic Labs has raised $5 billion to expand AI drug design and advance medicine candidates toward clinical trials. Photo: Isomorphic Labs
Research & Innovation

Isomorphic Labs Raises $5 Billion to Advance AI-Designed Medicines

Greenoaks and Sequoia Capital co-led the Series C as Demis Hassabis’ company expands its drug-design engine and prepares candidates for clinical trials.

By Laura Bennett • 3 mins read Edited by Samantha Reed Published: Updated:

Key Notes

  • Isomorphic Labs raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital, with further investment from Alphabet.
  • The funding will support its AI drug-design engine, medicine pipeline and the infrastructure needed to advance candidates toward clinical trials.
  • The company reports preclinical progress in internal oncology and immunology programs, rather than results from human trials.

Isomorphic Labs, the AI drug-discovery company led by Demis Hassabis, has raised $5 billion in Series C funding as it prepares to move therapeutic candidates toward clinical trials. CNBC reported the financing on November 17.

The company announced that Greenoaks and Sequoia Capital co-led the round, with participation from Andreessen Horowitz and further significant investment from Alphabet. Existing investors also participated.

The financing backs an expensive next stage for AI-designed medicines: developing the technology alongside the laboratory and clinical capabilities needed to test what it produces. Hassabis has led Isomorphic since it was founded in 2021; he stepped back as CEO of Google DeepMind earlier this year.

Building the Route From AI Models to Drug Trials

Isomorphic’s funding release says the proceeds will support its drug-design engine, known as IsoDDE, an expanding medicine pipeline and global bioengineering infrastructure. The company is also building translational and clinical-development capabilities as it advances candidates toward trials.

The company reports positive preclinical results in internal oncology and immunology programs, as well as partnered projects. That describes work before clinical entry. The announcement does not report human trial results or give a firm date for its first clinical program.

IsoDDE combines predictive and generative models to propose molecular designs, estimate their properties and refine them computationally before scientists decide which to make and test. Its tasks extend beyond predicting protein structures to questions such as where a molecule binds and how strongly it interacts with a target.

That is a broader problem than producing a convincing molecular structure. A potential medicine needs a useful combination of properties, and laboratory evidence must establish whether a design behaves as predicted. Clinical development then tests how that candidate performs in people.

Isomorphic also works with established drugmakers, including Novartis, Eli Lilly and Johnson & Johnson. Its portfolio therefore spans both wholly owned programs and research developed with pharmaceutical partners, rather than relying on a single route to market.

Another Multibillion-Dollar Round for AI Drug Discovery

The Series C follows Isomorphic’s $2.1 billion Series B in May, according to CNBC. The broadcaster also cited Dealroom data showing drug-discovery startups had raised a record $23.2 billion in 2026. That figure covers the category, rather than Isomorphic alone.

Other AI developers are moving deeper into medicine. Anthropic has begun working directly on drug-development programs, as AIstify reported. The growing investment reflects a race to connect model capabilities with experimental science.

For Isomorphic, the next milestones will be measured in the progress of drug candidates as well as model performance. The new capital gives it more resources to pursue that transition; the scientific and clinical outcomes will show what those resources deliver.

Disclaimer: AIstify is an independent media brand owned and operated by NuvexMedia LLC, publishing news, research, and insights on artificial intelligence, emerging technologies, automation, and related industries. NuvexMedia LLC invests in and collaborates with companies across the AI, technology, software, and digital innovation sectors. These relationships do not influence AIstify’s editorial coverage, and the publication maintains full editorial independence to provide accurate, timely, and objective information. © 2026 NuvexMedia LLC. All rights reserved. This content is for informational purposes only and should not be considered legal, tax, investment, financial, or other professional advice.

AI & Machine Learning, News, Research & Innovation, Startups & Investment